Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19412772 | 0.81 | JAK2 (0.40) | JAK2JAK1TYK2 | |
| SCHEMBL9915284 | 0.65 | KDM4E (0.31) | — | |
| SCHEMBL27947164 | 0.62 | — | — | |
| SCHEMBL23507843 | 0.62 | CYP3A4 (0.42) | — | |
| SCHEMBL32677379 | 0.62 | EGFR (0.37) | — | |
| SCHEMBL29071990 | 0.62 | EGFR (0.37) | — | |
| SCHEMBL18944640 | 0.61 | — | — | |
| SCHEMBL27816752 | 0.60 | NPSR1 (0.39) | — | |
| SCHEMBL26315547 | 0.60 | — | — | |
| SCHEMBL24893853 | 0.58 | PDPK1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185508-A1 | DEUTERATED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185508-A1 | DEUTERATED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, DIMT1, POLRMT | JAK2 4021/4885JAK1 3184/4885TYK2 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.